TECH - John L Higgins At Bio-Techne Capitalizes: Options Exercised Resulting In $300K | Benzinga
Highlighted on July 10, it was unveiled in an SEC filing that Higgins, Director at Bio-Techne (NASDAQ:TECH), executed a significant transaction involving the exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Higgins, Director at Bio-Techne, exercised stock options for 6,000 shares of TECH. The transaction value amounted to $300,960.
Bio-Techne shares are trading up 3.99% at $74.94 at the time of this writing on Thursday morning. Since the current price is $74.94, this makes Higgins's 6,000 shares worth $300,960.
Delving into Bio-Techne's Background
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Bio-Techne: Financial Performance Dissected
Positive Revenue ...